Compare Tempus AI (TEM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs TransMedics Group Inc — how do they compare? Tempus AI trades at $54.46 (market cap $10.05B), while TransMedics Group Inc trades at $87.46 (market cap $3.10B). The key difference: Tempus AI is far larger — about 3.2× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| TEM | TMDX | |
|---|---|---|
Market Cap | $10.05B | $3.10B |
Sector | Broad Market / Factor | Technology |
52-Week High | $103.25 | $150.42 |
52-Week Low | $41.55 | $61.99 |
Enterprise Value | $10.68B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $54.99, down 0.13% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed a narrower loss than expected and revenue beat, driving positive sentiment. The company is expanding through acquisitions like Personalis and launching new services, though it remains unprofitable with negative margins.
The outlook is cautiously optimistic due to revenue growth and strategic initiatives, but high valuation ratios and persistent losses pose risks. Upside is supported by a $61.57 consensus price target, while competitive and execution challenges require monitoring for sustained investor confidence.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
